UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 13F
FORM 13F COVER PAGE
Report for the Calendar Year or Quarter Ended: December 31, 1999
------------------
Check here if Amendment [ ]; Amendment Number:
-------------------------------
This Amendment (Check only one.): [ ] is a restatement.
[ ] adds new holdings entries.
Institutional Investment Manager Filing this Report:
Name: Perseus, L.L.C.
-------------------------------------
Address: The Army and Navy Club Building
-------------------------------------
1627 I Street, N.W., Suite 610
-------------------------------------
Washington, D.C. 20006
-------------------------------------
Form 13F File Number: 28-
--------------------
The institutional investment manager filing this report and the person by whom
it is signed hereby represent that the person signing the report is authorized
to submit it, that all information contained herein is true, correct and
complete, and that it is understood that all required items, statements,
schedules, lists, and tables, are considered integral parts of this form.
Person Signing this Report on Behalf of Reporting Manager:
Name: Rodd Macklin
----------------------------------------------------
Title: Chief Financial Officer, Treasurer and Secretary
----------------------------------------------------
Phone: (202) 452-0101
----------------------------------------------------
Signature, Place, and Date of Signing:
/s/ Rodd Macklin Washington, D.C. February 25, 2000
- --------------------------- -------------------------- ---------------------
[Signature] [City, State] [Date]
Report Type (Check only one.):
[X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager
are reported in this report.)
[ ] 13F NOTICE. (Check here if no holdings reported are in this report, and all
holdings are reported by other reporting manager(s).)
[ ] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this
reporting manager are reported in this report and a portion are reported by
other reporting manager(s).)
<PAGE>
FORM 13F SUMMARY PAGE
Report Summary:
Number of Other Included Managers: 0
---------------------
Form 13F Information Table Entry Total: 15
---------------------
Form 13F Information Table Value Total: $108,226
---------------------
(thousands)
List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file number(s) of all
institutional investment managers with respect to which this report is filed,
other than the manager filing this report.
NONE
<PAGE>
FORM 13F INFORMATION TABLE
<TABLE>
<CAPTION>
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
- ----------------------- -------------- --------- -------- ------------------- ---------- -------- ---------------------
VOTING AUTHORITY
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER ---------------------
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE
- ----------------------- -------------- --------- -------- ------- --- ---- ---------- -------- ---- ------ ----
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Millennium
Pharmaceuticals,
Inc. Common 599902103 $76,297 625,386 SH SOLE 625,386
- ------------------------------------------------------------------------------------------------------------------------------------
ILEX Oncology,
Inc. Common 451923106 $10,970 454,706 SH SOLE 454,706
- ------------------------------------------------------------------------------------------------------------------------------------
NetObjects, Inc. Common 64114L102 $14,729 892,668 SH SOLE 892,668
- ------------------------------------------------------------------------------------------------------------------------------------
Quintiles
Transnational Corp. Common 748767100 $187 10,000 SH SOLE 10,000
- ------------------------------------------------------------------------------------------------------------------------------------
Dura Pharmaceuticals,
Inc. Common 26632S109 $209 15,000 SH SOLE 15,000
- ------------------------------------------------------------------------------------------------------------------------------------
Texas Biotechnology
Corporation Common 88221T104 $119 15,000 SH SOLE 15,000
- ------------------------------------------------------------------------------------------------------------------------------------
Kendle International
Inc. Common 48880L107 $198 20,000 SH SOLE 20,000
- ------------------------------------------------------------------------------------------------------------------------------------
Celtrix
Pharmaceuticals, Inc. Common 151186103 $180 62,500 SH SOLE 62,500
- ------------------------------------------------------------------------------------------------------------------------------------
Regeneron
Pharmaceuticals, Inc. Common 75886F107 $159 12,500 SH SOLE 12,500
- ------------------------------------------------------------------------------------------------------------------------------------
Quidel Corporation Common 74838J101 $498 72,500 SH SOLE 72,500
- ------------------------------------------------------------------------------------------------------------------------------------
NPS Pharmaceuticals,
Inc. Common 62936P103 $306 25,000 SH SOLE 25,000
- ------------------------------------------------------------------------------------------------------------------------------------
Aurora Biosciences
Corporation Common 051920106 $398 15,000 SH SOLE 15,000
- ------------------------------------------------------------------------------------------------------------------------------------
Alkermes, Inc. Common 01642T108 $983 20,000 SH SOLE 20,000
- ------------------------------------------------------------------------------------------------------------------------------------
CareInsite, Inc. Common 14170M106 $765 9,500 SH SOLE 9,500
- ------------------------------------------------------------------------------------------------------------------------------------
Neurocrine Biosciences,
Inc. Common 64125C109 $2,228 90,000 SH SOLE 90,000
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
[Repeat as necessary]
</TABLE>
